Kalohexis 710GO data highlight a differentiated obesity mechanism as Phase 1 moves ahead
Read how Kalohexis’ 710GO could challenge GLP-1 obesity drugs with dual MC3R/MC4R activation, lean-mass sparing and durability.
Pharma & Biotech
Pharma & Biotech
How EOM Pharmaceutical Holdings is positioning EOM613 as a potential multi-cytokine therapy for cancer cachexia
Find out how EOM613 could reshape cancer cachexia treatment as EOM Pharmaceutical Holdings advances its FDA-cleared Phase 2a study.
Pharma & Biotech
Why the first patient dosed in CatalYm’s VINCIT trial matters more than it seems.
CatalYm has dosed the first patient in its visugromab Phase 2/3 cachexia trial. Read why this oncology move could matter far beyond weight gain.